A phase Ib/IIa study of INO-5401 in combination with REGN2810 a checkpoint inhibitor and INO-9012 in patients with newly-diagnosed glioblastoma multiforme (GBM)

Trial Profile

A phase Ib/IIa study of INO-5401 in combination with REGN2810 a checkpoint inhibitor and INO-9012 in patients with newly-diagnosed glioblastoma multiforme (GBM)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2017

At a glance

  • Drugs INO 5401 (Primary) ; INO 9012 (Primary) ; REGN 2810 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 10 May 2017 Inovio expects to begin enrollment in the second half of the year, according to a company media release.
    • 08 May 2017 According to an Inovio Pharmaceuticals media release, this study is expected to begin later 2017.
    • 08 May 2017 According to a Regeneron Pharmaceuticals media release, Regeneron Pharmaceuticals and Inovio Pharmaceuticals today announced a clinical study agreement for this trial, under the terms of the agreement, the trial will be solely conducted and funded by Inovio, and Regeneron will supply REGN2810, Inovio and Regeneron will jointly conduct immunological analyses in support of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top